30 results
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
product candidates GLPG5101 and GLPG5201, will be presented at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
dose-finding part of the study and preliminary data of the Phase 2 expansion part during a poster session at the 65th Annual American Society … future challenges.
Sustainability report Our commitment to society: Forward, Sustainably Pioneering science to transform patient outcomes
6-K
EX-99.1
GLPG
Galapagos NV
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
& NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation
6-K
EX-99.1
GLPG
Galapagos NV
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San
6-K
EX-99.1
ggwm78zx24kuwb0g92rb
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
bevr ec43g0d3thmy
2 May 23
Current report (foreign)
4:15pm
6-K
EX-99.1
o6751
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
j89z3d28 cl8xz
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
ey7rzbfd3 mx5tx3xp6
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
k2trnfxsw00aleu
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
EX-99.1
kwcar4cqo
28 May 21
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
6:00am
6-K
EX-99.1
j2k 4j7ym
19 May 21
Current report (foreign)
6:00am
6-K
EX-99.2
hsce0sv
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.1
hdmrzi4u6rjkib2z839d
21 Jan 21
Current report (foreign)
7:49am
6-K
EX-99.2
xvowhwv10pg 28h
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm
6-K
EX-99.1
0e7vem3oxpixpn
28 Sep 20
Current report (foreign)
6:00am
6-K
EX-99.1
t8nv80m3 suxk3iolus
26 Aug 20
Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress
6:37am
6-K
EX-99.2
568bg5wjsg
6 Aug 20
Galapagos reports solid H1 2020 progress
4:01pm